Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder affecting 1:3,500 individuals (1). The NF1 gene, located on chromosome 17, encodes neurofibromin, a GTPase-activating protein that binds and inactivates Ras proteins. NF1 is classified as a tumor suppressor gene (2). For example, NF1 patients are at increased risk for developing juvenile myelomonocytic leukemia and pilocytic astrocytomas (3, 4). The hallmark of NF1 is the development of Schwann cell precursor/Schwann cell–derived peripheral nerve sheath tumors, the formation of which is correlated with complete loss of NF1 expression (2, 5). In childhood, these are plexiform neurofibromas (pNF); tumors associated with larger nerves are found in 30% of patients with NF1 (4, 6). pNFs are diffuse tumors associated with larger nerves that can be disfiguring; the only current treatment is surgical resection. Growth of pNF is variable; irregular borders make volumetric calculations difficult to quantify. pNF can undergo malignant transformation to malignant peripheral nerve sheath tumors (MPNST; refs. 6, 7). MPNST are highly aggressive soft tissue sarcomas with poor prognosis (8). The annual incidence of NF1 patients developing MPNST has been estimated at 1.6 per 1,000, with a lifetime risk of 8% to 13% (9). MPNSTs behave aggressively, with a high rate of recurrence and a predilection to metastasize. Outcomes are favorable only when a small and localized tumor can be completely resected (10); adjuvant chemotherapy has no clear role. In the absence of multiple surgical biopsies, there is no reliable method for detecting pNF transformation to MPNST, although positron emission tomography scan can be helpful in some instances (11). Thus, alternative means of determining neurofibroma growth and transformation are needed.

In other oncologic processes, biomarkers play a key role in diagnosis and treatment. For example, α-fetoprotein secreted by germ cell tumors can indicate response to treatment and elevation of prostate-specific antigen is highly correlated with prostate malignancy (12, 13). Several investigators have collected serum from neurofibromatosis patients, but none have tested the relationship of serum proteins with tumor burden (14–16). PCR analysis of mRNA using Schwann cells in culture revealed several...
Adrenomedullin as an NF1 Serum Biomarker

Translational Relevance

The field of neurofibromatosis research is greatly hampered by the absence of markers of tumor burden. Using whole-genome microarray analysis and a secreted protein database, we identified upregulated transcripts in human plexiform neurofibromas (pNF) and MPNSTs. Further investigation revealed that adrenomedullin (ADM) was found in the serum of neurofibromatosis type 1 (NF1) patients at higher levels than controls and was also found at higher levels in the sera of patients with MPNST compared with those with pNF, suggesting that ADM may be a serum biomarker for malignant transformation. If validated in a larger study, serum levels of ADM could serve as an additional tool in the diagnostic repertoire of the physician when attempting to determine if a pNF has undergone malignant transformation.

Factors including basic fibroblast growth factor, platelet-derived growth factor, and midkine that are induced by loss of NF1. Midkine was also expressed in human neurofibromas, schwannomas, and various nervous system tumors associated with NF1 (17). Midkine and stem cell factor were found to be enriched in serum from NF1 patients, but these factors have not been correlated with tumor burden (9). Another protein, fetal antigen 1, was found in serum of NF1 patients (n = 13) at higher levels than in healthy controls (n = 177; P = 0.037; ref. 18). However, no large-scale study correlating tumor burden with serum markers has yet been carried out.

Because Schwann cells or their precursors are believed to represent the cell of origin of neurofibromas and MPNSTs, Miller et al. (19) compared Schwann cell expression with that of MPNST cell lines and primary MPNSTs and validated the MPNST cell line signature. Schwann cells were also compared with neurofibromas and MPNSTs. Here, we have integrated NF1 transcription data and the human secretome to identify potential serum biomarkers of pNF and/or MPNST. Two candidates [adrenomedullin (ADM) and hepatocyte growth factor (HGF)] emerged from our investigation as being potential biomarkers in patients with NF1.

HGF and its receptor, the tyrosine kinase c-Met, have been implicated in the growth of neoplasms (20) and are implicated in angiogenesis (21). A c-Met/HGF autocrine loop has been implicated in MPNST cell invasion (22). Indeed, HGF and c-Met are expressed by MPNSTs (23) and neurofibromas (23, 24), and HGF is a mitogen for Schwann cells (25).

ADM is a 52–amino acid secreted peptide that belongs to the calcitonin superfamily of peptides based on its structural similarity with calcitonin gene–related peptide and was originally isolated from a pheochromocytoma in 1993 (26). ADM also plays an essential role in growth of pheochromocytomas, neuroblastomas, glioblastomas, and other tumors (27). ADM has been identified as a secreted peptide involved in tumor-induced angiogenesis that results in neovascularization (28, 29) and hypoxia, upregulating ADM in human glioma cell lines as well as promoting glioma growth (30). ADM mRNA is increased in higher-grade gliomas and cell lines compared with normal brain (31). Further evidence of the role of ADM in tumor development is seen in a glioblastoma multiforme xenograft tumor model, in which administration of anti-ADM antibody greatly reduced both tumor growth and vascularity (31). We present data showing that ADM is increased in the serum of NF1 patients with MPNSTs and may affect MPNST biology via directly enhancing cell migration.

Materials and Methods

Microarray generation

Identification of candidate secreted biomarkers. We generated a list of candidate secreted NF1 biomarkers by intersecting genes statistically differentially expressed between cultured normal human Schwann cells (NHSC), Schwann cells derived from neurofibroma, and MPNST cell lines with proteins cataloged in the Secreted Protein Database (32). Specifically, 9,473 transcripts had been identified in a previous study comparing independent cultures of primary human Schwann cells (n = 10), dermal neurofibroma-derived Schwann cell cultures (n = 11), pNF-Derived Schwann cell cultures (n = 11), MPNST cell line cultures (n = 13), dermal neurofibromas (n = 13), pNFs (n = 13), and MPNSTs (n = 6; ref. 33). In brief, normalized samples using the Robust Multichip Analysis algorithm as implemented in Bioconductor/R (34) had been referenced by batch to controls for batch-to-batch variation, and the normalized expression of each gene in each sample to the median expression of the measurements of that transcript across 10 primary NHSC cultures referenced. We had corrected results from the primary analysis for multiple testing effects by applying the Benjamini and Hochberg false discovery rate correction (FDR ≤ 0.05; ref. 35). All statistical comparisons and data visualizations were done using GeneSpring GX v7.3.1 (Agilent Technologies). The data underlying this analysis can be accessed in Gene Expression Omnibus (accession number GSE14038 at http://www.ncbi.nlm.nih.gov).

For the current study, we initially focused on genes upregulated 1-fold or greater between NHSCs and primary neurofibroma or NHSCs and primary MPNST; 1,664 transcripts were upregulated in at least one of the two conditions. We separately imported 3,721 proteins from the Secreted Protein Database (32) into GeneSpring GX using RefSeq ID (confidence rank, 0–3). We then identified the intersection of the list of genes upregulated in NF1 cell cultures with the list of putative secreted proteins upregulated in primary tumors; 666 transcripts were identified. Subsequent cluster analysis across solid tumors (neurofibroma and MPNST) compared with NHSCs (33) identified the 132 most significantly upregulated transcripts (P < 0.001), of which 92 were unique genes and considered candidate secreted biomarkers.
Validation with quantitative real-time PCR. We used total RNA as a template to synthesize double-stranded cDNA using an oligo(dT) primer with SuperScript II reverse transcriptase (Invitrogen). We conducted duplicate reactions omitting reverse transcriptase to control for genomic DNA contamination. Relative levels of RNA were measured by quantitative real-time PCR (qPCR) using the ABI 7500 Sequence Detection System default settings. Amplification was conducted in SYBR Green Master Mix (Applied Biosystems). We obtained primer sequences using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), and oligonucleotides were purchased from Integrated DNA Technologies. The following primers were used: ADM, 5′-AGTCGTGGGAA-GAGGGAACT-3′ (forward) and 5′-CCCTGGAAGTTGT-TGATGCT-3′ (reverse); HGF, 5′-CTGGTTCCCCTTCAA-TAGCA-3′ (forward) and 5′-CTCCAGGGCTGACATTT-GAT-3′ (reverse); β-actin, 5′-GGACTTCGAGCAA-GAGATGG-3′ (forward) and 5′-ACATCTGCTGGAAGGTG-GAC-3′ (reverse). The remainder of the candidate primers are shown in Supplement 1. Cycle threshold values were obtained, where fluorescence intensity was in the geometric phase of amplification, and averaged for triplicate reactions. Values for individual genes of interest were normalized to values for β-actin and used to calculate fold change in gene expression using ABI software.

ADM and HGF detection in serum-free conditioned medium. MPNST cell lines (described in ref. 19) were grown to 90% confluence in DMEM with 10% fetal bovine serum (FBS). Medium was removed and cells were washed three times with PBS. We then added serum-free DMEM (Fisher Scientific) and removed the medium after 48 hours. We centrifuged the supernatant at 10 × g for 5 minutes to remove cellular debris.

Migration assay. We measured the migratory response of 8814 MPNST cells using a modified Boyden chamber assay. Cells (4 × 10^4) in serum-free DMEM were plated on the upper chamber of a 24-well Transwell plate with 8-μm pore membranes (Costar, Corning, Inc.). The lower chamber contained 800 μL of 8814 MPNST conditioned medium. Cells were incubated for 24 hours at 37°C in 10% CO₂. Nonmigrating cells were removed from the upper surface of the membrane with cotton swabs. Membranes were stained with bisbenzimide and mounted onto glass slides. For each condition, migration was quantified by counting cells in four nonoverlapping fields in three independent membranes. Samples were evaluated in three independent experiments, and data from a representative experiment are shown. Numbers of migrated cells were normalized to the total number of cells on an unscraped filter to validate the total number of cells plated. ADM and ADM 22-52 (a competitive receptor antagonist) were from Bachem Bioscience, Inc. Data shown are representative of three independent experiments; values presented are the mean ± SD. We determined statistical significance by Student’s t test using GraphPad Prism software.

Patient serum. Serum specimens and corresponding clinical data were collected and used in accordance with a Cincinnati Children’s Hospital Medical Center (CCHMC) Institutional Review Board (IRB)–approved protocol. All patients from Cincinnati Children’s monthly NF1 comprehensive genetics clinic who had documented pNFs were approached to provide a serum sample. We procured blood samples from 32 NF1 patients. Serum was separated within 3,721 proteins from the Secreted Protein Database identified in GeneSpring GX using RefSeq ID

1,664 transcripts from the 3,721 are upregulated in neurofibromas and MPNSTs relative to NHSC

666 transcripts overlap

132 transcripts with a P value of <0.001 were secreted or predicted to be secreted and similarly differentially expressed in cell cultures and similarly up- or downregulated in solid tumors

92 unique genes identified

13 candidates analyzed

Fig. 1. NF1 biomarker list generation and validation flowchart.
1 hour of collection and kept at −80°C until analyzed. One sample was from an NF1 patient with a pNF who had previously consented to donate serum and subsequently developed an MPNST. We obtained 25 frozen surplus serum samples from the Cincinnati Children’s Hospital Clinical Laboratory, which were used as controls. Only age and gender of the surplus serum were revealed in accordance with a CCHMC IRB-approved protocol. Genetics, hematology/oncology, and bone marrow transplant patients were excluded.

**ELISA**

We conducted ELISA assays on serum-free conditioned medium and human serum using an ADM detection kit (Phoenix Pharmaceuticals) and Human HGF ELISA kit (R&D Systems) following the manufacturer’s suggested protocol. We did all assay procedures in triplicate. Internal negative and positive quality controls were provided in each ELISA kit and run in triplicate in each assay.

**Tube formation**

Human umbilical vascular endothelial cells (HUVEC) were purchased from Lonza. HUVECs maintained in EBM2 medium (Lonza) with supplement (supplied by Lonza) were washed twice with PBS, trypsinized, and plated (4 × 10^5 cells/mL) in wells of 96-well plates coated with Matrigel (BD Biosciences) in either DMEM or EBM2 with 2% FBS supplemented with ADM (10 μmol/L), ADM 22-52 (10 μmol/L), both ADM and ADM 22-52, HGF (10 ng/mL), or anti-HGF antibody (0.5 μg/mL) in triplicate. After 18 hours, the plates were stained using calcein-AM (8 μg/mL) and two nonoverlapping fields per well were photographed using a fluorescent microscope, accounting for >80% of the area of each filter. Three wells were analyzed per experimental condition. Three independent experiments were conducted, and data from a representative experiment are shown. The area of tube formation was then quantified using ImageJ software.

**Results**

**Biomarker list generation and validation**

A flowchart outlining the methodology used to generate a candidate NF1 biomarker list is shown in Fig. 1. We used transcription data collected and analyzed by the NF1 Systems Biology and Microarray Consortium (33) and integrated it with cataloged in the Secreted Protein Database (32). After importing 3,721 RefSeq IDs corresponding to proteins cataloged in the Secreted Protein Database, we focused on 1,664 transcripts that were upregulated in cells and primary tumors relative to NHSCs. Of the 1,664 transcripts, 132 were similarly upregulated in both neurofibroma-derived Schwann cell cultures and primary tumors and secreted or predicted to be secreted from the Secreted Protein Database, after imposing a P value of 0.001. After correcting for transcript variants, 92 genes were identified to encode putative secreted proteins and statistically differentially expressed and upregulated in neurofibroma-derived Schwann cell cultures and primary tumors.

<table>
<thead>
<tr>
<th>Microarray confirmation</th>
<th>qPCR validation: fold change (range)</th>
<th>Confirmed in MPNST cell conditioned medium</th>
<th>Confirmed in patient serum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NFSC</td>
<td>MPNST</td>
<td>Western blot</td>
</tr>
<tr>
<td>EFEMP1</td>
<td>Failed</td>
<td>Failed</td>
<td>Not done</td>
</tr>
<tr>
<td>MEGF10</td>
<td>Failed</td>
<td>Failed</td>
<td>Not done</td>
</tr>
<tr>
<td>KIAA0114</td>
<td>Failed</td>
<td>Failed</td>
<td>Not done</td>
</tr>
<tr>
<td>CTGF</td>
<td>Failed</td>
<td>Failed</td>
<td>Not done</td>
</tr>
<tr>
<td>NOS3</td>
<td>Failed</td>
<td>Failed</td>
<td>Not done</td>
</tr>
<tr>
<td>FA1</td>
<td>Failed</td>
<td>Failed</td>
<td>Not done</td>
</tr>
<tr>
<td>NPTX2</td>
<td>Failed</td>
<td>159 (7-382)</td>
<td>Failed</td>
</tr>
<tr>
<td>HSPD1</td>
<td>8 (4-13)</td>
<td>11 (4-24)</td>
<td>Failed</td>
</tr>
<tr>
<td>IGF1</td>
<td>4 (3-5)</td>
<td>3 (3-4)</td>
<td>Not done</td>
</tr>
<tr>
<td>MMP9</td>
<td>4 (2-13)</td>
<td>428 (15-2,003)</td>
<td>Not done</td>
</tr>
<tr>
<td>DAF</td>
<td>6 (2-13)</td>
<td>22 (2-51)</td>
<td>Not done</td>
</tr>
<tr>
<td>HGF</td>
<td>4 (1-8)</td>
<td>273 (86-917)</td>
<td>Not done</td>
</tr>
<tr>
<td>ADM</td>
<td>44 (13-70)</td>
<td>70 (6-193)</td>
<td>Not done</td>
</tr>
</tbody>
</table>

*NOTE:* Those candidates that did not fail confirmation have their respective fold change with range in parentheses listed. Quantitative reverse transcription-PCR (Failed = tested in designated experiment and did not confirm at 3-fold or greater change in expression). Data represent mean fold change across cells from four individual patients; range is shown in parentheses. Data represent mean fold change across eight cell lines; range is shown in parentheses. Candidates whose differential expression was confirmed by PCR were investigated for presence in MPNST serum-free medium by Western blot or ELISA (Failed = not detected). ADM and HGF were confirmed in cell conditioned medium and investigated in patient serum via ELISA.
Thirteen candidates were chosen for further validation, as they exhibited robust differential expression predicted by the microarray data. Additional criteria for pursuing validation were literature reports of involvement in oncologic processes and/or commercially available reagents. Seven of 13 candidates were validated by qPCR (i.e., differentially expressed in neurofibroma Schwann cells (NFSC) and MPNST versus NHSCs at the mRNA level. Of these seven, two candidates were detected in serum-free conditioned medium and investigated further (Table 1).

ADM and HGF were chosen from the list of 92 genes due to the role of HGF in cell growth and motility and its binding to the proto-oncogenic c-Met receptor (36). ADM was chosen due to its known effects on tumor growth in other cancer models (27). Both candidates exhibited robust expression profiles across all cell lines and primary tumors when compared with NHSCs, and their expression was validated at the RNA level by quantitative qPCR. Figure 2 shows the marked upregulation of ADM and HGF in both MPNST cell lines and neurofibroma-derived primary Schwann cells (NF1+/- and NF1−/−) when compared with NHSCs. Intriguingly, there is a decrease in differential expression in the NF1−/− cell strains versus the NF1+/− Schwann cell strains. More samples would be required to determine whether this is a genotype effect or reflects differences among cells from different individuals.

Four of eight tested MPNST cell lines remained viable in serum-free medium for at least 48 hours, enabling collection of conditioned medium. We found that the concentration of ADM in serum-free conditioned medium ranged from 0.152 to 1.072 ng/mL in MPNST cell lines. HGF in MPNST serum-free conditioned medium ranged from 0.426 to 25.01 ng/mL. A sporadic MPNST cell line (STS26T) exhibited the lowest amount of HGF in serum-free conditioned medium at 0.052 ng/mL. This was significant compared with 0.052 ng/mL of HGF in NHSC conditioned medium (Fig. 3A and B). All four tested MPNST cell lines contained ADM and HGF in conditioned medium, suggesting secretion of both HGF and ADM by MPNST cells.

Serum ADM and HGF levels in NF1 patients

Based on ADM and HGF secretion into MPNST conditioned medium, we reasoned that these proteins might be detectable in the serum of patients with NF1 or might be elevated in the serum of patients with significant tumor burden. To test these ideas, we collected serum samples from NF1 patients with and without pNF as well as NF1 patients with MPNST. Thirty-two patients with NF1...
consented to have blood drawn for analysis. Ten patients did not have pNF, whereas 17 patients had documented pNF, defined by clinical exam and imaging (computed tomography or magnetic resonance imaging). The age and gender distribution of the 32 participating NF1 patients are shown in Table 2. One patient was diagnosed with an MPNST of the abdomen 2 weeks after collection, and the corresponding serum was grouped with the MPNST serum samples.

The mean ADM serum concentration in controls was 0.07 ng/mL (n = 25), significantly lower (P < 0.0001) than serum ADM levels in NF1 patients with (n = 17) or without (n = 10) pNF (mean serum ADM concentration of 0.18 ng/mL for both groups; Fig. 3C). The mean ADM serum concentration in controls was also significantly lower than the mean serum concentration for NF1 patients with MPNSTs (mean ADM concentration of 0.24 ng/mL; P < 0.0001). There were no differences in mean ADM serum levels when comparing NF1 patients with pNF and NF1 patients without pNF. In addition, there was no difference in ADM serum levels when comparing age, gender, or location of pNF. However, mean ADM concentration in NF1 patients with MPNSTs had significantly higher ADM levels when compared with NF1 patients with pNF (mean ADM concentration of 0.24 versus 0.18 ng/mL; P = 0.03). In contrast, HGF was not significantly different in the serum of controls (1.1 ng/mL) compared with NF1 patients with pNF (1.0 ng/mL), NF1 patients without pNF (0.95 ng/mL), or NF1 patients with MPNSTs (1.5 ng/mL; Fig. 3D).

**ADM stimulates migration of MPNST cells**
ADM is implicated in the biology of neuroblastoma and glioblastoma as well as lung, breast, and ovarian neoplasms (27, 37), in both tumor cell proliferation and migration...
to elucidate whether MPNST serum-free conditioned medium, shown above to contain ADM and HGF, would stimulate endothelial tube formation. As a control, ADM and HGF were added to EGM2 (HUVEC base medium) and shown to induce more proliferation than baseline (data not shown). ADM and HGF inhibitors were also tested in EGM2 and shown to reduce HUVEC tube formation (data not shown). Serum-free conditioned media from 8814 (NF1-associated MPNST) and 26T (sporadic MPNST) were likewise tested on HUVECs. Area of tube formation was then compared with that of HUVECs in serum-free DMEM. The respective MPNST conditioned medium was subsequently combined with ADM and HGF inhibitors; the results of which are shown in Fig. 4C and D.

**NF1-associated MPNST serum-free conditioned medium stimulates HUVEC tube formation**

HGF and ADM each stimulate proliferation in HUVECs (21, 42, 43), and vascularity may be associated with poorer prognosis in some tumors (44, 45). We did experiments

### Table 2. Characteristics of the NF1 patients whose serum was drawn for analysis

<table>
<thead>
<tr>
<th>NF1 without pNF</th>
<th>NF1 with pNF</th>
<th>MPNST Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total 10</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td>NF1 9</td>
<td>17</td>
<td>5</td>
</tr>
<tr>
<td>Sibling control</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Male 7</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Female 3</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>Age (y) Range</td>
<td>13-42</td>
<td>5-42</td>
</tr>
<tr>
<td>Mean</td>
<td>21</td>
<td>19</td>
</tr>
<tr>
<td>Median</td>
<td>17</td>
<td>16</td>
</tr>
</tbody>
</table>

**Abbreviation:** n/a, not applicable or unknown.

Discussion

The present study describes integration of NF1 transcriptional data and human proteins known or predicted to be secreted. From a list of 92 putative secreted NF1 biomarkers, we identified two candidates: ADM and HGF. ADM and HGF mRNA differential expression were validated by qPCR. Both proteins are secreted in serum-free conditioned medium from sporadic and NF1-associated MPNST cell lines. We show that ADM is a serum biomarker of NF1; NF1 patients with and without pNF, and with MPNST, have significantly increased serum concentrations of ADM compared with controls. We also show that ADM has cell-autonomous effects on MPNST migration. Whereas 13 candidates were initially investigated, another 79 candidates have yet to be validated. Further investigation of these candidates using serum-free conditioned medium and the sera of patients with pNF and MPNST as described above could lead to additional biomarkers and potential therapeutic targets.

Previous investigations have illustrated the benefit of using microarrays to arrive at biomarkers that may predict neoplasm development. Dhanasekaran et al. (46) used microarrays in prostate cancer and were able to delineate hepsin and pim-1 proteins as potential biomarkers in prostate cancer. Other studies have taken further steps, similar to those described in this study, in elucidating potential biomarkers. Mok et al. used microarrays to identify over-expressed genes for secretory proteins and confirmed in patient sera via ELISA that prostasin may be a serum biomarker for ovarian cancer. Prostasin, when studied in combination with the known biomarker CA-125, has a sensitivity of 92% and a specificity of 94% in detecting...
ovarian carcinomas (47). In 2005, Huddleston et al. discovered that creatine kinase B (CKB) is overexpressed in ovarian carcinoma cell lines compared with normal cell lines on microarray analysis. ELISA-based assays were also subsequently done on serum samples from patients with ovarian carcinoma, patients with benign pelvic masses, and normal controls. CKB gene expression was found to be upregulated in ovarian cancer cells in vitro and in vivo and that CKB enzyme activity is significantly elevated in sera from ovarian cancer patients, suggesting a potential role for CKB as a marker for early diagnosis (48). Although the use of microarray technology to elucidate a serum biomarker is not a novel concept, this is the first report in the literature of the use of a microarray-generated biomarker specific for NF1 and MPNST.

Other studies have documented increased serum levels of ADM in neuroendocrine tumors (49). However, there are no previous literature reports of ADM being studied in the serum of human sarcomas or NF1-associated tumors. We found that serum levels of ADM are elevated in patients with NF1 regardless of tumor status, similar to a previous report of fetal antigen 1 (18). In addition, because ADM levels were significantly higher in NF1 patients with MPNST than pNF, our data suggest that ADM may be a serum biomarker for malignant transformation. Larger studies should be done to confirm these findings as well as compare these.

![Graphs showing ADM and HGF support migration of MPNST cells, and NF1 MPNST cell conditioned medium supports endothelial cell tube formation.](image)

**Fig. 4.** ADM and HGF support migration of MPNST cells, and NF1 MPNST cell conditioned medium supports endothelial cell tube formation. A, NF1-associated MPNST cell migration is stimulated by ADM and by MPNST serum-free conditioned medium. B, sporadic MPNST cell migration is stimulated by ADM and MPNST serum-free conditioned medium. ADM was used at 10 μmol/L, ADM 22-52 (Inhib) was used at 10 μmol/L. Student’s t test compared controls with each individual experimental group. C, NF1-associated MPNST conditioned medium stimulates HUVEC tube formation. D, sporadic MPNST conditioned medium does not stimulate HUVEC tube formation compared with controls. EGM2, HUVEC base medium including serum, fibroblast growth factor, and platelet-derived growth factor; DMEM, serum-free DMEM; 8814 CM, serum-free conditioned medium (NF1-associated MPNST cell line); 26T CM, serum-free conditioned medium (sporadic MPNST cell line); ADM, 10 μmol/L ADM; ADM inhib, 10 μmol/L ADM 22-52; HGF, 10 ng/mL HGF; HGF inhib, 0.5 μg/mL HGF inhibitor.
markers to other prognostic tools such as \(^{18}\)F]2-fluoro-2-deoxy-D-glucose positron emission tomography scans.

ADM might also be relevant to tumor growth. However, the amounts of ADM required to stimulate tube formation and migration experiments are higher than those identified in patient serum. We have not evaluated the local concentration in the tissue to the concentrations used \textit{in vitro}, yet we note that concentrations in dense cells \textit{in vivo} are high enough to generate effects on migration and tube formation. In addition, the 26T MPNST cells are not stimulated to grow by NF1-specific 8814 MPNST conditioned medium, whereas 26T MPNST conditioned medium is able to stimulate migration in 8814 MPNST cells. This discrepancy could be due to NF1-specific MPNST cells being more sensitive to the effects of ADM, a hypothesis further reinforced in the tube formation experiments. A limitation of this study is the small MPNST sample size; a larger series of MPNST patients\' sera should be screened to validate these findings. Another limitation to our data interpretation is the use of surplus sera as controls. The characteristics of these sera were not fully defined apart from age and gender. Although we excluded patients with other tumors, the control sera used for this analysis could have come from patients who may have had other disease processes, such as liver disease or urinary tract infections (50, 51), which may have abnormal levels of ADM and/or HGF. In addition, only four of eight MPNST cell lines were viable in serum-free medium. As such, results using conditioned medium may be biased toward a subset of MPNSTs that may represent a biologically meaningful subgroup. However, the microarray data showed an increase in expression across all neurofibromas and MPNSTs, which argues against the possibility of such bias.

HGF did not prove to be a serum biomarker in NF1 patients with tumors, although HGF was highly expressed in our transcriptome analysis. Although serum levels in NF1 patients did not suggest its use as a biomarker, HUVEC tube formation data support the idea that HGF contributes to growth of MPNST \textit{in vitro} via stimulation of angiogenesis. HUVEC tube formation was inhibited by the addition of ADM and HGF antagonists in the presence of NF1-associated MPNST serum-free conditioned medium, confirming that MPNSTs secrete angiogenic factors, including HGF and ADM. We have shown that NF1-specific MPNST serum-free conditioned medium contains higher levels of ADM and HGF than sporadic MPNST conditioned medium. Unlike sporadic MPNST serum-free conditioned medium, NF1-associated MPNST serum-free conditioned medium stimulates tube formation in HUVECs. Additionally, ADM was shown to have specific MPNST cell-autonomous effects on cell migration. These findings identify the potential involvement of ADM in NF1-associated MPNST pathology and reinforce the potential involvement of HGF (23, 24). Further confirmatory investigation is warranted, as treatment with anti-HGF antibodies could be a potential therapeutic option for NF1-associated MPNST, especially as the use of monoclonal antibodies to HGF for treatment of HGF/c-Met–dependent tumors is in clinical phase I trials (52).

In summary, we have shown the feasibility of integrating gene expression data with known or predicted secreted proteins to select potential NF1 biomarkers. We identify one candidate, ADM, as a biomarker for pNF and NF1-associated MPNST. Larger prospective studies will be required to confirm this finding and rigorously test further elevation of ADM serum levels in patients with MPNSTs.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were identified.

**Grant Support**

N. Ratner is supported by the Department of Defense (DAMD-1-W1XWH-04-1-0273). S.C. Miller was supported by K01-NS049191. V.F. Mautner is supported in part by Rudolf Bartling Stiftung II/85 (Hanover, Germany) and in part by the U.S. Department of Defense (NF043115). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 03/09/2010; revised 06/09/2010; accepted 08/04/2010; published OnlineFirst 08/25/2010.

**References**

11. Ferrier RE, Golding JF, Smith M, et al. \(^{18}\)F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic
Adrenomedullin as an NF1 Serum Biomarker


Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-0613

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/01/13/1078-0432.CCR-10-0613.DC1

Cited articles
This article cites 51 articles, 19 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/16/20/5048.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/16/20/5048.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.